DrugDashboards

Methylprednisolone sodium succinate

Methylprednisolone sodium succinate · METHYLPREDNISOLONE SODIUM SUCCINATE 40 mg/mL · Injection · Intramuscular; Intravenous · Dr. Reddy's Laboratories Inc

NDC 43598-0127-25 · 25 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$120.00
Reported to Texas DSHS · 2026 annual filing · Dr. Reddy's Laboratories, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 5 MG
$0.224
HCPCS J2919 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$21,787
3,241 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for methylprednisolone sodium succinate (injectable) in the next 90 days

sterile injectable · sole-source market · price up 4% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA212396
TE code
AP
Approval date
Apr 20, 2021
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Methylprednisolone sodium succinate (Injection)

LabelerStrengthFirst seenLast seen
Dr. Reddy's Laboratories IncMETHYLPREDNISOLONE SODIUM SUCCINATE 1 g/16mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories IncMETHYLPREDNISOLONE SODIUM SUCCINATE 125 mg/2mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories IncMETHYLPREDNISOLONE SODIUM SUCCINATE 40 mg/mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories IncMETHYLPREDNISOLONE SODIUM SUCCINATE 500 mg/8mLJul 15, 2026Sep 2, 2026
Remedyrepack Inc.METHYLPREDNISOLONE SODIUM SUCCINATE 125 mg/2mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstMETHYLPREDNISOLONE SODIUM SUCCINATE 125 mg/2mLJul 15, 2026Jul 22, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Methylprednisolone sodium succinate — NDC 43598-0127-25," retrieved September 3, 2026, https://drugdashboards.com/drug/43598012725.

Free to cite with attribution — see how the data is put together.